Picras-3-en-16-one, 13,20-epoxy-2-(β-D-glucopyranosyloxy)-1,11,12,14,15-pentahydroxy-, (1β,2α,11β,12α,15β)-

Request For Quotation
Picras-3-en-16-one, 13,20-epoxy-2-(β-D-glucopyranosyloxy)-1,11,12,14,15-pentahydroxy-, (1β,2α,11β,12α,15β)- Suppliers list
Company Name: Wuhan ChemFaces Biochemical Co., Ltd.  
Tel: 18607101326 15172504745
Email: aileen@chemfaces.com
Company Name: Shanghai YuanYe Biotechnology Co., Ltd.  
Tel: 18916372613
Email: yanzihan@shyuanye.com
Company Name: Chengdu Push Bio-Technology Co., Ltd.  
Tel: 028-85370565-229 18080489829
Email: 18080489829@163.com
Company Name: Beijing Jin Ming Biotechnology Co., Ltd.  
Tel: 010-60605840
Email: psaitong@jm-bio.com
Company Name: Chengdu Bioanseis Phytochemicals Co., Ltd.  
Tel: 13518187787
Email: 632977132@qq.com
Picras-3-en-16-one, 13,20-epoxy-2-(β-D-glucopyranosyloxy)-1,11,12,14,15-pentahydroxy-, (1β,2α,11β,12α,15β)- Basic information
Product Name:Picras-3-en-16-one, 13,20-epoxy-2-(β-D-glucopyranosyloxy)-1,11,12,14,15-pentahydroxy-, (1β,2α,11β,12α,15β)-
Synonyms:Picras-3-en-16-one, 13,20-epoxy-2-(β-D-glucopyranosyloxy)-1,11,12,14,15-pentahydroxy-, (1β,2α,11β,12α,15β)-;Yadanzigan
CAS:76588-87-9
MF:C26H38O14
MW:574.57
EINECS:
Product Categories:
Mol File:76588-87-9.mol
Picras-3-en-16-one, 13,20-epoxy-2-(β-D-glucopyranosyloxy)-1,11,12,14,15-pentahydroxy-, (1β,2α,11β,12α,15β)- Structure
Picras-3-en-16-one, 13,20-epoxy-2-(β-D-glucopyranosyloxy)-1,11,12,14,15-pentahydroxy-, (1β,2α,11β,12α,15β)- Chemical Properties
Melting point 243-245 °C
Boiling point 835.5±65.0 °C(Predicted)
density 1.68±0.1 g/cm3(Predicted)
pka11.47±0.70(Predicted)
Safety Information
MSDS Information
Picras-3-en-16-one, 13,20-epoxy-2-(β-D-glucopyranosyloxy)-1,11,12,14,15-pentahydroxy-, (1β,2α,11β,12α,15β)- Usage And Synthesis
UsesYadanzigan (YDZG) is an anti-inflammatory agent and a NLRP3 inhibitor. Yadanzigan specifically inhibits NLRP3 activation via inhibiting NF-κB pathway and Reactive Oxygen Species production. Yadanzigan also moderates LPS (HY-D1056)-induced acute lung injury (ALI) in mice[1].
in vivo

Yadanzigan (5 mg/kg, 10 mg/kg; i.v.; dose for 3 times) prevents LPS-induced acute lung injury in mouse model[1].

Animal Model:Male BABL/C mice (18-22 g)[1]
Dosage:5 mg/kg, 10 mg/kg
Administration:Intravenous injection; dose at 2 h prior to and 6 h, 12 h after LPS induction
Result:Reduced LPS-induced infiltration of inflammatory cells and cytokine levels, such as TNF-α and IL-6. Inhibited NLRP3 inflammasome activation in lung tissue.
Resulted significantly greater survival rate.
IC 50NLRP3 inflammasome
References[1] Cui Y, et al. Yadanzigan, a quassinoid glucoside, attenuates NLRP3 inflammasome activation to prevent LPS-induced acute lung injury. Authorea Preprints, 2020.
Picras-3-en-16-one, 13,20-epoxy-2-(β-D-glucopyranosyloxy)-1,11,12,14,15-pentahydroxy-, (1β,2α,11β,12α,15β)- Preparation Products And Raw materials
Tag:Picras-3-en-16-one, 13,20-epoxy-2-(β-D-glucopyranosyloxy)-1,11,12,14,15-pentahydroxy-, (1β,2α,11β,12α,15β)-(76588-87-9) Related Product Information
NLRP3 Protein, Human (His) Y-27632 Adenosine triphosphate MitoSOX N-Acetyl-L-cysteine Triptolide